There are two loud stories about hormone therapy and neither of them is much use to a woman trying to decide.
The older story is that it causes cancer and was abandoned for good reason. The newer story is that it was unfairly maligned, that the fear was a mistake, and that most women should be on it. The first story is out of date. The second one overshoots.
What follows is the structure of the decision rather than the answer to it. The answer depends on your history, and nobody writing an article knows your history.
What hormone therapy actually is
It replaces hormones your ovaries have largely stopped producing, at doses far lower than a contraceptive pill and much closer to what your body used to make on its own.1 2
That is the whole idea. It is not a stimulant, an anti ageing treatment, or a fertility treatment. It treats symptoms caused by a shortage, and it stops working when you stop taking it.
The two components, and why the second exists
Estrogen does the symptom work. It is the part that reduces flushes, night sweats, dryness and bone loss.
If you still have a uterus, estrogen on its own gradually thickens the womb lining, and over time that raises the risk of womb cancer. So a second hormone, a progestogen, is given alongside it to keep the lining thin.16 That is its entire job in this context.
If your uterus has been removed, the lining is not there to protect, and estrogen alone is used. This matters because most of the difference in the risk picture between women comes from exactly this split.
The forms it comes in
Estrogen can be taken as a tablet, worn as a patch, rubbed on as a gel or spray, or given as a small implant. The progestogen part can be a tablet, part of a combined patch, or supplied by a hormonal coil sitting in the uterus, which has the side benefit of handling contraception at the same time.
The form is not a matter of preference alone. A tablet is swallowed and passes through your liver before it reaches the rest of you, and that first pass changes how your body handles clotting proteins. A patch or gel goes in through your skin and skips that step.
This is why current guidance in many countries leans towards skin delivery for women who have any additional clot risk, such as a previous clot, a strong family history, migraine with aura or a higher body weight.11
Vaginal estrogen is a separate treatment
If your main problems are dryness, discomfort during sex, or recurring urinary infections and urgency, there is a low dose estrogen applied locally as a cream, gel, tablet or ring.
Because so little of it reaches the rest of your body, it is not carrying the same risk conversation as tablets or patches. It can often be used by women who cannot take systemic hormone therapy, though that is a decision for a clinician, particularly after breast cancer.15 10
It is also the treatment most women are never offered, despite genital and urinary symptoms being the ones that do not improve on their own with time. Flushes usually fade eventually. Dryness generally does not.
What it reliably does
Hot flushes and night sweats respond better to estrogen than to anything else available.4 7 This is the least contested part of the whole field.
It protects bone. Estrogen loss accelerates bone thinning in the years around the final period, and hormone therapy slows that and reduces fractures while it is being taken.14
Sleep frequently improves, largely because being woken by heat five times a night stops happening. Mood and concentration often improve alongside, for the same reason.
Local symptoms respond well to local treatment, usually within a few weeks.
What it does not do
It is not a general purpose tonic. It will not reverse ageing, guarantee weight loss, or fix fatigue that has another cause.
It is not a treatment for depression, and it does not replace one.
It is not contraception. Pregnancy stays possible until twelve months have passed without a period.5 6
And it is not a substitute for the ordinary inputs. Sleep, protein, strength training and alcohol still influence how you feel, on or off hormones.
The risks, stated plainly
Three risks come up, and they are not the same size.
Breast cancer. Combined therapy is linked to a small increase in risk that grows with duration of use and falls back after stopping. Estrogen alone does not show the same pattern. The increase from combined therapy is modest in absolute terms, comparable to the difference associated with regular drinking or with carrying significant extra weight. That comparison is meant as scale, not as permission. If you have a strong family history, your starting point is different and the conversation should reflect that.3
Blood clots. Tablets carry a small increase in the risk of clots in the legs or lungs. Patches and gels do not appear to carry the same increase, because they do not pass through the liver first. For a woman with no other clot risk, the tablet risk is still small. For a woman with several, the route choice matters.
Stroke. Oral estrogen is associated with a small increase in stroke risk, which rises with age. Skin delivery again looks more favourable. The absolute numbers for a woman in her early fifties are low.12
What happened in 2002, and what is understood now
In 2002 a large American study of hormone therapy was stopped early and reported worldwide as showing that it caused breast cancer and heart problems. Prescribing collapsed within months in several countries, and a generation of doctors was trained in the aftermath.
Two things went wrong in how it was read.
The first was relative risk reported without absolute numbers. The headline increase sounded dramatic. Translated into how many additional women were affected, it was small.
The second was age. The women studied were on average in their sixties, and many were more than a decade past their final period. That is not the group who typically ask for treatment. Later analysis separated the results by age, and the picture for women who started in their fifties looked considerably different from the headline.
What is understood now is not that the study was wrong. Its findings for older women who start late still stand. It is that the results were applied to a much broader group than they were ever able to describe.
The timing question
Out of that reanalysis came the idea that when you start matters as much as what you take.
Started near the transition, generally under sixty or within ten years of the final period, the balance of benefit against risk looks favourable for most women with symptoms. Started much later, the same treatment looks less favourable, with cardiovascular risk being the main reason.13
The likely explanation is that estrogen behaves differently in blood vessels that are still relatively healthy than in vessels that have already accumulated years of change. That explanation is reasonable rather than settled, and honest sources describe it as a working model.
Who is usually not offered it
Current or past breast cancer, some other hormone sensitive cancers, unexplained vaginal bleeding that has not been investigated, active liver disease, and a recent or current blood clot all mean systemic hormone therapy is either avoided or handled by a specialist.
None of these are automatic permanent bans in every case, and local vaginal treatment is sometimes still possible. They are reasons for a specialist conversation rather than a general practice one.
What the first three months look like
Expect an adjustment period. Breast tenderness, some bloating, headaches and irregular bleeding are common early on and usually settle within about three months.
Doses and forms are often adjusted once or twice before something fits. Concluding after two weeks that it does not work is the most common way women abandon a treatment that would have suited them.
Persistent bleeding beyond a few months, however, is not something to wait out. It should be reported and looked at.
Where testosterone fits
Women produce testosterone too, and levels fall gradually with age rather than dropping sharply at menopause. In several countries a low dose is prescribed for one specific reason: persistent low sexual desire that is causing distress and has not improved on estrogen alone.
Two things are worth knowing. It is usually prescribed in addition to estrogen rather than instead of it, and in many places no product is licensed for women, so a male preparation is used at a fraction of the dose. That is normal practice and it is also a reason it needs proper monitoring rather than being obtained privately without follow up.
Testosterone is not an energy treatment, a body composition treatment or a general tonic for midlife, whatever the marketing suggests. The evidence supports the desire indication and does not currently support the rest.
How long women stay on it
There is no fixed stopping date, and the old advice to come off after five years regardless has largely been abandoned as too blunt.
The realistic approach is an annual review: what symptoms would return if you stopped, what your risk picture looks like now that you are older, and whether the form still suits you. Some women take it for two years and are done. Others continue for much longer with the balance reassessed each time.
Coming off is usually done by reducing gradually rather than stopping abruptly, because a sudden withdrawal can bring symptoms back sharply and make it hard to tell whether they had actually resolved.
Women with an early menopause are a distinct group here. Treatment is generally advised at least until the usual age of menopause, because the concern in that situation is not symptom control but the effect of many additional years without estrogen on bone and heart health.8 9
If you would rather not, or cannot
Non hormonal prescription options exist for flushes, and some are genuinely effective. Structured psychological approaches have decent evidence for reducing how disruptive flushes and night waking feel, even without changing how often they occur.
Reducing alcohol, treating sleep problems directly, and strength training for bone all matter regardless of the hormone decision, and they are not consolation prizes.
When your symptoms are not about hormones
Before settling into a hormone decision, it is worth confirming there is nothing else in the frame.
An underactive thyroid produces fatigue, weight change, low mood and cycle disruption that overlaps almost completely.17 Iron deficiency produces exhaustion, breathlessness and poor concentration, and is common alongside heavy bleeding in the transition. Sleep apnoea, anaemia, diabetes, depression and side effects of existing medication all belong on the list.
How to have the conversation
Come with three things: what your worst symptom is, what your personal and family history contains, and what you have already tried.
Reasonable questions to ask are which form is being suggested and why, whether skin delivery is appropriate for you, whether local treatment would cover your main symptom on its own, what would count as this working, and when you will be reviewed.
If you leave without knowing what happens in three months, the appointment is not finished.
The honest limits
There is no version of this decision with no uncertainty in it. The evidence is strong on flushes and bone, reasonable on timing, and genuinely contested on some longer term questions including brain health.
What is not contested is that the decision belongs to you and the clinician who knows your history, and that both the fear inherited from 2002 and the enthusiasm of the current backlash are poor substitutes for that conversation.